Epitomee Medical Ltd (TA:EPIT) — Market Cap & Net Worth
Market Cap & Net Worth: Epitomee Medical Ltd (EPIT)
Epitomee Medical Ltd (TA:EPIT) has a market capitalization of $26.17 Million (ILA9.76 Billion) as of July 22, 2026. Listed on the TA stock exchange, this Israel-based company holds position #24191 globally and #343 in its home market, demonstrating a -7.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Epitomee Medical Ltd's stock price ILA324.60 by its total outstanding shares 30072865 (30.07 Million). See Epitomee Medical Ltd (EPIT) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Epitomee Medical Ltd Market Cap History: 2021 to 2026
Epitomee Medical Ltd's market capitalization history from 2021 to 2026. Data shows change from $254.77 Million to $26.17 Million (-42.38% CAGR).
Epitomee Medical Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Epitomee Medical Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.99x
Epitomee Medical Ltd's market cap is 2.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $29.93 Million | $10.00 Million | -$5.68 Million | 2.99x | N/A |
Competitor Companies of EPIT by Market Capitalization
Companies near Epitomee Medical Ltd in the global market cap rankings as of July 22, 2026.
Key companies related to Epitomee Medical Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $176.77 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #196 globally with a market cap of $122.13 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #235 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #240 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $176.77 Billion | $101.66 |
| #196 | Stryker Corporation | NYSE:SYK | $122.13 Billion | $319.14 |
| #235 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #240 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $83.29 |
Epitomee Medical Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Epitomee Medical Ltd's market cap moved from $254.77 Million to $ 26.17 Million, with a yearly change of -42.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA26.17 Million | -46.85% |
| 2025 | ILA49.24 Million | -33.32% |
| 2024 | ILA73.84 Million | +146.71% |
| 2023 | ILA29.93 Million | -67.89% |
| 2022 | ILA93.20 Million | -63.42% |
| 2021 | ILA254.77 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of Epitomee Medical Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.17 Million USD |
| MoneyControl | $26.17 Million USD |
| MarketWatch | $26.17 Million USD |
| marketcap.company | $26.17 Million USD |
| Reuters | $26.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.